A patient-specific, 3D printed neurostimulator enabling focal transcranial electrical stimulation and EEG at home.
Mahyar Joodaki, Griffin Rodgers, Alois Hopf and 9 others
PMID 41287086WHAT IT FOUND
In computer models of ten head shapes, a custom 3D-printed cap produced a more consistent target stimulation field, and eight healthy users completed all sessions with no serious adverse effects.
It shows device usability, not that stimulation treats a condition.
Key findings
01In simulations using head models from ten healthy subjects, optimized montages produced a mean target electric field of 0.290 ± 0.005 V/m, while fixed HD montages produced 0.113 ± 0.028 V/m.
02Across 32 one-hour tACS sessions in eight healthy participants, all completed the sessions and no serious adverse device effects were reported.
03Dry brush electrodes recorded EEG signals that closely matched wet cup electrodes, with adjacent-pair signal correlation close to 0.99.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The clinical study was exploratory, single-arm, and small: ten participants consented for MRI use, but only eight completed the full protocol, so it cannot show treatment benefit. It tested healthy people in a clinic, not patients at home over weeks or months, so home use and clinical populations remain unproven. The main stimulation comparisons were computer simulations, not measured electric fields in living brains, so they show predicted dose rather than delivered dose. Cap misplacement matters: simulated rotations beyond 15 mm changed the field pattern and increased off-target intensity, but real-world repeated placement was not benchmarked across many head shapes. Dry electrodes did not always give low enough impedance for tACS; wet mode was below 15 kΩ for all subjects and positions, while dry mode was below 50 kΩ for most subjects and positions, and gel may be needed. Personalization usually needs MRI, which may not be routine for conditions such as depression, and the custom device may be less cost-effective for short-term use.
Declared interests
Bottneuro AG, which developed the Miamind neurostimulator, electrodes, and gel adaptor, is named as a funder, along with Innosuisse.
The easy way to misread this
Do not conclude that this device treats depression or Alzheimer's disease. It was tested in eight healthy participants for safety and usability, not in patients, and it had no control group.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →